Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
18 sep 2014 - 07:42
Statutaire naam
Galapagos NV
Titel
Galapagos reports high participation rate in long term extension study with GLPG0634 in RA patients
Bericht
Mechelen, Belgium; 18 September 2014 - Galapagos NV (Euronext: GLPG) announced today that more than 100 patients have completed the six month Darwin 1 and 2 studies with GLPG0634 in rheumatoid arthritis and entered Darwin 3, the long term extension study. With the support of their treating physicians, over 90% of the patients who participated in Darwin 1 and Darwin 2 have chosen to participate in Darwin 3, in which all patients will receive long term treatment with Galapagos' highly selective JAK1 inhibitor.
Datum laatste update: 23 december 2025